Product Description
selected Mesenchymal stromal cells derived from human umbilical cord
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Belfast Health and Social Care Trust
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Kidney Diseases|ANCA Vasculitis
Phase 2: Acute Respiratory Distress Syndrome|Cholangitis, Sclerosing|Hepatitis, Autoimmune
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Merlin | P2 |
Active, not recruiting |
Cholangitis, Sclerosing|Hepatitis, Autoimmune |
2023-11-23 |
|
Repair of ARDS by Stromal Cell Administration (REALIST) | P2 |
Unknown status |
Acute Respiratory Distress Syndrome |
2021-12-06 |
|
TXCoronavac | P3 |
Not yet recruiting |
Kidney Diseases|ANCA Vasculitis |
2021-02-01 |